- Report
- October 2023
- 78 Pages
United States
From €3346EUR$3,500USD£2,875GBP
- Report
- October 2023
- 186 Pages
Global
From €5258EUR$5,500USD£4,518GBP
- Report
- November 2023
- 177 Pages
Global
From €4684EUR$4,900USD£4,026GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1912EUR$2,000USD£1,643GBP
- Report
- April 2023
- 110 Pages
Global
From €4541EUR$4,750USD£3,902GBP
- Report
- January 2022
- 110 Pages
Global
From €4541EUR$4,750USD£3,902GBP
- Report
- April 2021
- 47 Pages
Global
€21032EUR$22,000USD£18,074GBP
- Report
- February 2021
- 254 Pages
Global
From €10511EUR$10,995USD£9,033GBP
- Report
- February 2021
- 58 Pages
Global
From €3819EUR$3,995USD£3,282GBP
- Report
- April 2019
Global
From €7170EUR$7,500USD£6,162GBP
- Report
- May 2023
- 160 Pages
Global
From €5735EUR$5,999USD£4,928GBP
Pre Exposure Prophylaxis (PrEP) is a form of HIV prevention that involves taking a daily pill to reduce the risk of HIV infection. PrEP is a combination of two antiretroviral drugs, tenofovir and emtricitabine, which are used to treat HIV. PrEP is recommended for people who are at high risk of HIV infection, such as men who have sex with men, transgender women, and people who inject drugs. PrEP is highly effective in preventing HIV infection when taken as prescribed.
PrEP is available in many countries around the world, and is becoming increasingly accessible. PrEP is typically prescribed by a healthcare provider and is available in both generic and branded forms. The cost of PrEP varies depending on the country and the type of drug prescribed.
Several pharmaceutical companies are involved in the PrEP market, including Gilead Sciences, Mylan, and Teva Pharmaceuticals. Gilead Sciences is the largest manufacturer of PrEP drugs, with its branded drug Truvada being the most widely used PrEP drug. Mylan and Teva Pharmaceuticals also produce generic versions of PrEP drugs. Show Less Read more